Cart
sales@molnova.com
BCI-137
CAS No. 112170-24-8
BCI-137( BCI 137 | BCI137 )
Catalog No. M27752 CAS No. 112170-24-8
BCI-137 is an Argonaute 2 ligand. It acts by targeting the MicroRNA Binding Domain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 85 | In Stock |
|
| 10MG | 121 | In Stock |
|
| 25MG | 207 | In Stock |
|
| 50MG | 300 | In Stock |
|
| 100MG | 449 | In Stock |
|
| 200MG | 641 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBCI-137
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCI-137 is an Argonaute 2 ligand. It acts by targeting the MicroRNA Binding Domain.
-
DescriptionBCI-137 is an Argonaute 2 ligand. It acts by targeting the MicroRNA Binding Domain.
-
In Vitro——
-
In Vivo——
-
SynonymsBCI 137 | BCI137
-
PathwayOthers
-
TargetOther Targets
-
RecptorLPS-TLR4/MD2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number112170-24-8
-
Formula Weight313.28
-
Molecular FormulaC11H11N3O6S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (319.19 mM)
-
SMILESCC(NS(=O)(=O)c1ccc2[nH]c(=O)c(=O)[nH]c2c1)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yi Wang, et al. Curcumin Analog L48H37 Prevents Lipopolysaccharide-Induced TLR4 Signaling Pathway Activation and Sepsis via Targeting MD2. J Pharmacol Exp Ther. 2015 Jun;353(3):539-50
molnova catalog
related products
-
Ilexhainanoside D
Ilexhainanoside D is a natural product from Periploca sepiumBge.
-
Alphalipoic acid
Thioctic acid is an octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
